Healthcare · NIFTY 500

Glenmark Pharmaceuticals Limited

NSEGLENMARK BSE532296 ISININE935A01035 SeriesEQ Listed on NSE · BSE

₹2,659.80 -17.40 (-0.65%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+40.37% in a year

Today

Open: ₹2,665.00
Prev close: ₹2,677.20
Day high: ₹2,680.00
Day low: ₹2,634.00
Volume: 9.04 L
Value traded: ₹240.42 Cr
Upper circuit: ₹2,733.60
Lower circuit: ₹2,574.40
52W high: ₹2,682.50
52W low: ₹1,801.40
1 month: +18.15%
6 months: +10.34%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹75,065 Cr

P/E (TTM)51.74

P/B6.69

Book value / share₹397.29

EPS (TTM)₹51.41

ROE7.9%

Dividend yield0.09%

Dividend (12m)₹2.50 / share

Net margin (TTM)5.6%

Operating margin11.8%

Debt / equity0.08

Current ratio1.69

EV / EBITDA31.51

Sales growth (YoY qtr)-31.25%

Profit growth (YoY qtr)-100.00%

Sales CAGR 3Y+9.34%

Profit CAGR 3Y—

Shares28.22 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

2,507-351

Dec 23

3,063-1,218

Mar 24

3,244340

Jun 24

3,4340.0

Sep 24

3,3880.0

Dec 24

3,2564.7

Mar 25

3,26446.9

Jun 25

6,047610

Sep 25

3,901403

Dec 25

3,771-0.1

Mar 26

4,018483

Jun 26

4,1570.0

Sep 26

Revenue · QoQ (vs last quarter)

—+22%+5.9%+5.8%-1.3%-3.9%+0.3%+85%-35%-3.3%+6.6%+3.4%

Revenue · YoY (vs a year ago)

————+35%+6.3%+0.6%+76%+15%+16%+23%-31%

Net profit · QoQ (vs last quarter)

—-247%+128%-100%——+908%+1,202%-34%-100%+508,441%-100%

Net profit · YoY (vs a year ago)

————+100%+100%-86%——-102%+930%-100%

RevenueNet profitLine = trend

-12.45

Dec 23

-43.18

Mar 24

12.06

Jun 24

12.55

Sep 24

12.33

Dec 24

0.16

Mar 25

1.66

Jun 25

21.62

Sep 25

14.28

Dec 25

10.68

Mar 26

17.11

Jun 26

9.34

Sep 26

EPS (₹) · YoY (vs a year ago)

————+199%+100%-86%+72%+16%+6,575%+931%-57%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	2,507	3,063	3,244	3,434	3,388	3,256	3,264	6,047	3,901	3,771	4,018	4,157
Other income	45.4	773	31.5	39.4	31.1	11.7	26.4	201	44.5	189	65.8	92.8
Total income	2,552	3,836	3,276	3,473	3,419	3,268	3,291	6,247	3,945	3,960	4,084	4,250
Raw material	658	754	686	774	746	795	732	723	775	731	601	838
Purchases	413	211	360	443	418	345	581	620	749	446	661	530
Employee cost	753	701	710	787	788	737	763	1,086	841	887	935	1,028
Other expenses	930	862	835	975	915	870	906	1,337	894	948	1,033	1,050
Total expenses	2,997	2,859	2,813	3,001	2,962	2,887	2,872	3,895	3,227	3,199	3,441	3,628
Operating profit	-285	57.6	588	602	600	188	257	974	685	389	805	490
OPM %	-11.4%	1.9%	18.1%	17.5%	17.7%	5.8%	7.9%	16.1%	17.6%	10.3%	20.0%	11.8%
Finance cost	134	149	39.6	48.5	52.3	66.7	58.2	66.5	41.4	42.6	54.0	63.8
Depreciation	147	151	118	120	123	125	130	141	154	148	173	180
Exceptional items	-76.7	-447	—	—	—	-373	-323	-1,385	-184	-373	—	-284
Profit before tax	-521	531	462	473	456	8.0	95.6	967	534	388	643	338
Tax	-71.8	1,769	122	118	108	3.6	48.6	357	131	86.4	161	74.5
Net profit	-331	-1,214	340	354	348	4.4	47.0	610	403	301	483	264
Profit to shareholders	-351	-1,218	—	0.0	0.0	4.7	46.9	610	403	-0.1	483	0.0
EPS (₹)	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.62	14.28	10.68	17.11	9.34

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

9,8651,7530.0

FY19

10,6411,7310.0

FY20

10,9442,1290.0

FY21

12,3052,059942

FY22

12,9901,5130.0

FY23

11,813294-1,502

FY24

13,3221,9791,047

FY25

16,9832,3060.1

FY26

Revenue · YoY (vs a year ago)

—+7.9%+2.8%+12%+5.6%-9.1%+13%+27%

Net profit · YoY (vs a year ago)

————-100%—+170%-100%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	9,865	10,641	10,944	12,305	12,990	11,813	13,322	16,983
Other income	208	160	50.2	167	317	840	114	461
Total expenses	8,940	9,737	9,656	10,769	11,673	11,716	11,663	13,192
Employee cost	2,056	2,255	2,344	2,447	2,781	2,868	3,022	3,578
Operating profit	1,753	1,731	2,129	2,059	1,513	294	1,979	2,306
OPM %	17.8%	16.3%	19.5%	16.7%	11.6%	2.5%	14.9%	13.6%
Finance cost	335	377	353	298	350	516	207	209
Depreciation	326	417	444	487	611	582	486	573
Profit before tax	1,301	1,096	1,382	1,441	868	36.5	1,399	1,985
Tax	376	320	412	448	491	1,867	352	623
Tax rate %	28.9%	29.2%	29.8%	31.1%	56.5%	5,116.7%	25.2%	31.4%
Net profit	925	776	970	994	377	-1,434	1,047	1,362
Profit to shareholders	0.0	0.0	0.0	942	0.0	-1,502	1,047	0.1
Net margin %	0.0%	0.0%	0.0%	7.7%	0.0%	-12.7%	7.9%	0.0%
EPS (₹)	32.78	27.50	34.38	33.37	10.53	-53.22	37.10	48.24

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

9,4744,3481,443

Mar 23

7,8489911,658

Mar 24

8,8492,1941,676

Mar 25

10,5121,175

Mar 26

11,2128671,290

Sep 26

Shareholders' equity · YoY (vs a year ago)

—-17%+13%+19%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	9,474	7,848	8,849	10,512	11,212
Long-term borrowings	3,852	0.0	513	0.0	0.0
Short-term borrowings	496	991	1,681	0.0	867
Total borrowings	4,348	991	2,194	—	867
Current liabilities	5,046	5,819	5,967	6,376	7,507
Fixed assets (PPE)	3,904	3,118	3,319	3,890	3,307
Inventories	2,978	2,513	3,029	3,431	3,746
Trade receivables	4,099	1,858	3,342	4,963	5,494
Cash & equivalents	1,443	1,658	1,676	1,175	1,290
Current assets	9,874	7,428	9,295	11,300	12,714
Total assets	19,372	14,359	16,050	19,908	21,400
Debt / equity	0.46	0.13	0.25	—	0.08

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

1,109-333-520

FY22

625-528-77.5

FY23

-2654,369-3,906

FY24

-8282.1787

FY25

3,445-1,283-2,709

FY26

Operations · YoY (vs a year ago)

—-44%-142%-212%+516%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,109	625	-265	-828	3,445
Cash from investing	-333	-528	4,369	2.1	-1,283
Cash from financing	-520	-77.5	-3,906	787	-2,709
Spent on fixed assets	-790	-608	-898	-750	-1,358
Free cash flow	319	17.6	-1,164	-1,577	2,087
Net cash flow	255	19.4	198	-38.5	-547

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

46.7%Dec 23

46.6%Mar 24

46.7%Jun 24

46.7%Sep 24

46.7%Dec 24

46.7%Mar 25

46.7%Jun 25

46.7%Sep 25

46.7%Dec 25

46.7%Mar 26

46.7%Jun 26

46.7%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

46.7%promoter

Promoter & group: 46.65%
Public (FIIs, mutual funds, retail…): 53.35%
Promoter change, last quarter: 0.00 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 2.50 Per ShareEx 31-Aug-2026
Interim Dividend - Rs 2.50 Per ShareEx 03-Oct-2025
Dividend - Rs 2.50 Per ShareEx 15-Sep-2025
Dividend - Rs 2.50 Per ShareEx 13-Sep-2024
Dividend - Rs 2.50 Per ShareEx 18-Sep-2023
Annual General Meeting/Dividend - Rs 2.50 Per ShareEx 12-Sep-2022
Annual General Meeting/Dividend - Rs 2.50 Per ShareEx 08-Sep-2021
Annual General Meeting/Dividend - Rs 2.50 Per ShareEx 17-Sep-2020

Board meetings

GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaud…05-Nov-2026
the financial results for the period ended September 30, 202605-Nov-2026
GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 31-Jul-2026 to inter-alia consider and approve the Unaud…31-Jul-2026
the financial results for the period ended Jun 30, 202631-Jul-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.29-May-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates6 Nov
Updates5 Nov

Latest news

GLENMARK Outlook for the WeekEquitypandit · 8 Nov, 1:30 pm Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pm Glenmark Pharma shares fall despite better-than-expected US sales in Q2, 14% growth in India businessCNBC TV18 · 6 Nov, 7:19 am Glenmark Q2FY27 Results: Transcript uploaded after audio releasescanx.trade · 9 Nov, 5:11 pm Why Has Glenmark's Share Price Jumped Over 5% Today?Dalal Street Investment Journal · 6 Nov, 2:54 pm Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 crThe Economic Times · 5 Nov, 8:08 pm Stock to buy today: Glenmark Pharmaceuticals (₹2,270) – BUYBusinessLine · 7 Jul, 12:30 pm Glenmark Pharma shares soar 2% on plans to launch potassium phosphates injection USPUpstox · 15 Mar, 12:30 pm

About

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. We unite scientific excellence, responsible execution and commercial agility to effectively address unmet patient needs of today and proactively anticipate the emerging health needs of tomorrow.The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark.

From Wikipedia (CC BY-SA 4.0).

BRANDS

Episoft

Company details

Company name: Glenmark Pharmaceuticals Limited
NSE symbol: GLENMARK
BSE scrip code: 532296
ISIN: INE935A01035
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 7 Feb 2000
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 28.22 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Glenn Saldanha
Chair: Glenn Saldanha
Headquarters: Mumbai
Registered address: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai - 400 099, Maharashtra, India
Founded: 1977
Employees: 17,782
Financial year: April to March
Results basis: Consolidated
Website: glenmarkpharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Glenmark Pharmaceuticals Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers